Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report.
An 80-year-old man with advanced adenocarcinoma of the prostate received cyproterone acetate, 200 mg orally per day as sole treatment. Striking regression of the tumour was demonstrated by ultrasonograms and excretory urograms. Serum concentrations of acid phosphatases, gonadotrophins, and testosterone decreased significantly. No significant cardiovascular side effects occurred.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000368:Aged; D003534:Cyproterone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010907:Pituitary Hormones / Q000097:blood; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D013739:Testosterone / Q000097:blood
D010907:Pituitary Hormones; D013739:Testosterone; D003534:Cyproterone; D000135:Acid Phosphatase